Optiflow™

Improving patient care and outcomes
by reducing patient escalation across
the care continuum.

Therapy or Product Enquiry


Were you looking for...

A story of
Optiflow High Flow (HF) therapy in use

Clinical evidence 
related to
Optiflow HF therapy

FAQs about
Optiflow HF therapy

A way to contact us

Optiflow™ Nasal High Flow at the Royal Berkshire Hospital

Introducing Optiflow to the Royal Berkshire Hospital - a multi-department implementation

This video shows the usage of AIRVO 2 and Optiflow HF therapy in different departments (higher monitoring unit and ICU) of the Royal Berkshire Hospital in Reading, UK. It shows the benefits they have found both to the patients and hospital since its introduction.

By clicking the play button on the video you are confirming that you are a healthcare professional
and entitled to watch this.
(3 minutes long)


Using Optiflow to reduce the escalation of care for patients

HFNC, HFOT, NHF, HF...

While many acronyms have been used for this therapy, one name stands out as the way to deliver it: Optiflow HF.
Optiflow HF therapy from Fisher & Paykel Healthcare is at the forefront of the field, featuring in hundreds of publications and appearing in such prestigious journals as the NEJM and JAMA. Using Optiflow HF therapy as a first-line treatment (both pre-intubation and post-extubation) may reduce a patient’s escalation “up the acuity curve”, resulting in better patient outcomes and reduced costs of care.

 



“Use of NHF reduced the risk of reintubation within 72 hours.”

(among extubated patients at low risk of reintubation).

~ Hernández. et al. JAMA. Apr 2016.



“NHF significantly
reduced the need for intubation in more acute patients.”

(compared to standard O2 and NIV, PaO2:FiO2 ≤ 200 mmHg).

~ Frat et al. New Engl J Med. 2015.


“NHF was non-inferior to BPAP for preventing reintubation and respiratory failure.”

(among extubated patients post cardiothoracic surgery).

~ Stéphan et al. JAMA. 2015.

View clinical evidence


Ready to evaluate Optiflow, in the ED, ICU or on a general floor?

Experience Optiflow HF therapy
in real patients, across the care continuum.

Make an evaluation enquiry and your local
Fisher & Paykel Healthcare representative
will arrange a visit to you and your team.


Enquire about evaluating Optiflow


How does Optiflow work?

The mechanisms of action

With Optiflow HF therapy, you can independently titrate flow and FiO2 to match your patient’s needs. The mechanisms
of action differ from those of conventional therapies, as do the resulting physiological effects and clinical outcomes.
 

Optiflow Mechanisms
Optiflow High Flow deadspace mechanism overview

Reduction of
deadspace overview

Watch the video above to find out more about how the reduction of deadspace mechanism works.

Optiflow High Flow airway hydration mechanism overview

Airway hydration overview

Watch the video above to find out more about how the airway hydration mechanism works.

Optiflow High Flow pressure mechanism overview

Dynamic positive airway pressure overview

Watch the video above to find out more about how the dynamic positive airway pressure mechanism works.

The Optiflow HF therapy mechanisms of action are: 

  • Respiratory support (through the reduction of dead space
    and delivery of a dynamic positive airway pressure)
  • Airway hydration
  • Patient comfort
  • Supplemental oxygen (if required)

These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels, and improved mucus clearance.

Clinical studies suggest that Optiflow HF therapy may decrease the escalation of care, reduce mortality rates, and improve symptomatic relief

FAQ

The 5 most frequently asked questions about Optiflow

1. Is there a NHF protocol for AHRF patients? | 2. What flow rates and ranges are used? | 3. How much pressure is generated? | 
4. When are the effects of Optiflow HF therapy seen? | 5. Is there a way to predict the outcome of HF?

Visit our FAQ page


What about the economics -
does Optiflow make good financial sense?

Health systems worldwide are confronted by the need to reduce costs - or avoid them altogether.
The findings of recent Optiflow HF therapy studies, particularly those of Frat and Hernández, show that the use
of Optiflow HF both pre-intubation and post-extubation, may reduce escalation and avoid its associated costs.
 

Optiflow health economics graph

A patient’s journey through hospital may include periods of escalation and de-escalation of care.
Consider this conceptual model, above, showing two patients’ journeys through hospital.
The costs for these journeys are denoted by the areas of light blue and dark blue.

Enquire about evaluating Optiflow

Flow Matters – Optiflow newsletter.
Keep up to date with the latest in Optiflow HF therapy clinical research.

 

Flow Matters - Issue 8

Flow Matters

Issue 8

Focus: first published clinical protocol detailing the application of high flow therapy for adult patients with acute hypoxemic respiratory failure.

Download
Go With Flow - Issue 7

Go with the flow

Issue 7 

Focus: Optiflow post extubation.
Using Optiflow HF therapy to
reduce the risk of reintubation.

 
 
Go With The Flow Issue 6

Go with the flow

Issue 6 

Focus: Optiflow HF therapy is
non-inferior to BPAP for
cardiothoracic surgery patients
with or at risk of respiratory failure.
 

Optiflow technology

Fisher & Paykel Healthcare technology was the first choice for the important studies published
in NEJM and JAMA, securing the place of Optiflow at the forefront of this exciting therapy.

F&P AIRVO 2

Airvo™ 2 System

Optiflow™+ Nasal Cannula

F&P MR850 Humidifier

MR850 System

Webinar focused on home use
of Nasal High Flow in patients
with chronic disease

Associate Professor Ulla Møller Weinreich speaks about
her research on humidified high flow therapy for patients
with chronic disease in this Nasal High Flow webinar.
 

Primary Outcome (intention to treat analysis)


Exacerbation rates (of chronic disease) were significantly lower in patients in the NHF + long term oxygen therapy (LTOT) group compared with the LTOT only group

Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long–term effects of oxygen–enriched high–flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018; 13:1195–205.

 

 

Want to receive updates?

Sign up to receive email notifications of the latest product and therapy information as well as upcoming events.
 

Sign up here

Download List

Optiflow Newsletter - Issue 6

(PDF 0.4MB)

Download

Optiflow Newsletter - Issue 7

(PDF 0.4MB)

Download

Optiflow Adult Clinical Paper Summaries

(PDF 2.0MB)

Download

Optiflow Therapy Brochure

(PDF 0.9MB)

Download

Optiflow Flow Matters Newsletter - Issue 8

(PDF 0.1MB)

Download


References


Using Optiflow to reduce the escalation of care for patients

  1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015;372(23):2185–96.
View additional references


How does Optiflow work?

Reduced respiratory rate
  1. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011; 37(11):1780–6.
  2. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011; 107(6):998–1004.
View additional references


What about the economics -
does Optiflow make good financial sense?

  1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015;372(23):2185–96.
View additional references